<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Insulin Therapy in Type 1 Diabetes — Quick Reference Algorithm</title>
  <meta name="description" content="One‑page quick reference algorithm for insulin therapy in Type 1 diabetes (NICE CKS based). Clean, modern, printable." />
  <style>
    :root{
      --bg: #0f172a;          /* slate-900 */
      --muted:#64748b;        /* slate-500 */
      --ink:#0b1220;          
      --paper:#f8fafc;        /* slate-50 */
      --card:#ffffff;
      --accent:#0ea5e9;       /* sky-500 */
      --accent-2:#22d3ee;     /* cyan-400 */
      --good:#16a34a;         /* green-600 */
      --warn:#f59e0b;         /* amber-500 */
      --bad:#ef4444;          /* red-500 */
      --shadow: 0 10px 25px rgb(2 8 23 / 0.15);
      --radius: 18px;
      --radius-sm: 12px;
      --radius-lg: 26px;
      --maxw: 1100px;
    }
    [data-theme="dark"]{
      --paper:#0b1220; 
      --card:#0f172a;
      --ink:#e5e7eb; 
      --muted:#94a3b8; 
      --shadow: 0 10px 25px rgb(148 163 184 / 0.15);
    }
    html,body{height:100%;}
    body{
      margin:0;
      font: 16px/1.55 system-ui, -apple-system, Segoe UI, Roboto, Inter, "Helvetica Neue", Arial, Noto Sans, "Apple Color Emoji", "Segoe UI Emoji";
      color: var(--ink);
      background: radial-gradient(1200px 600px at 10% -10%, rgba(14,165,233,.18), transparent 60%),
                  radial-gradient(900px 500px at 100% -20%, rgba(34,211,238,.22), transparent 60%),
                  var(--paper);
    }
    .wrap{max-width:var(--maxw); margin-inline:auto; padding: 28px 18px 80px;}

    /* Header */
    header.hero{
      position: relative;
      padding: 26px;
      border-radius: var(--radius-lg);
      background: linear-gradient(135deg, rgba(14,165,233,.15), rgba(34,211,238,.12));
      box-shadow: var(--shadow);
      overflow:hidden;
      backdrop-filter: blur(4px);
    }
    .kicker{display:inline-flex; gap:8px; align-items:center; font-weight:600; letter-spacing:.02em; color:var(--muted);}
    .kicker .pill{display:inline-flex; align-items:center; gap:6px; padding:6px 10px; border-radius:999px; background: rgba(14,165,233,.12); color:#0b7285; font-size:.85rem; border:1px solid rgba(14,165,233,.25)}
    .title{margin:10px 0 8px; font-size: clamp(28px, 4.2vw, 40px); line-height:1.15; letter-spacing:-0.02em}
    .subtitle{color:var(--muted); max-width: 70ch}

    /* Toolbar */
    .toolbar{display:flex; gap:10px; align-items:center; justify-content:flex-end; margin-top:14px; flex-wrap:wrap}
    .btn{appearance:none; border:none; border-radius:12px; background: var(--ink); color: #fff; padding:10px 14px; font-weight:600; cursor:pointer; display:inline-flex; gap:8px; align-items:center; box-shadow: var(--shadow);}
    .btn.secondary{background:#0ea5e9;}
    .btn.ghost{background:transparent; color:var(--ink); border:1px solid rgba(100,116,139,.35)}
    .btn svg{width:18px;height:18px;}

    /* Quick Nav */
    .nav{
      position: sticky; top:10px; z-index:9; margin: 18px 0 22px; backdrop-filter: blur(6px);
      background: linear-gradient(135deg, rgba(255,255,255,.65), rgba(255,255,255,.45));
      border:1px solid rgba(100,116,139,.25); color:#020617;
      padding:10px; border-radius: 999px; box-shadow: var(--shadow);
    }
    [data-theme="dark"] .nav{ background: linear-gradient(135deg, rgba(2,6,23,.75), rgba(2,6,23,.55)); color:#e2e8f0}
    .nav ul{list-style:none; display:flex; gap:10px; margin:0; padding:0; flex-wrap:wrap; align-items:center}
    .nav a{display:inline-flex; align-items:center; gap:8px; padding:8px 12px; border-radius:999px; text-decoration:none; font-weight:600; color:inherit; border:1px solid rgba(100,116,139,.25)}
    .nav a:hover{background:rgba(14,165,233,.15); border-color:rgba(14,165,233,.35)}

    /* Sections */
    section{margin: 24px 0}
    .grid{display:grid; gap:16px}
    @media (min-width: 860px){ .grid{grid-template-columns: repeat(12, 1fr);} }

    .card{grid-column: 1 / -1; background: var(--card); border-radius: var(--radius); box-shadow: var(--shadow); padding: 18px 18px 14px; border:1px solid rgba(100,116,139,.18)}
    .card h3{margin:0 0 6px; font-size: clamp(18px, 2.2vw, 22px)}
    .eyebrow{display:flex; gap:8px; align-items:center; color:var(--muted); font-weight:700; letter-spacing:.02em; text-transform:uppercase; font-size:.78rem}
    .meta{color:var(--muted); font-size:.95rem}

    .cols{columns:1; column-gap:28px}
    @media (min-width: 820px){ .cols{columns:2;} }
    .cols ul{margin:8px 0 0; padding-left:1.1rem}

    .badge{display:inline-flex; align-items:center; gap:6px; padding:4px 8px; border-radius:999px; font-weight:700; font-size:.8rem; border:1px solid rgba(100,116,139,.25)}
    .badge.good{background: rgba(22,163,74,.12); color:#065f46; border-color: rgba(22,163,74,.25)}
    .badge.warn{background: rgba(245,158,11,.12); color:#8a4b00; border-color: rgba(245,158,11,.25)}
    .badge.info{background: rgba(14,165,233,.12); color:#0b7285; border-color: rgba(14,165,233,.25)}

    .callout{border-left: 6px solid var(--accent); padding: 10px 12px; background: linear-gradient(90deg, rgba(14,165,233,.12), transparent 60%); border-radius: 10px;}

    .list-tight li{margin:6px 0}

    .twocol{
      display:grid; gap:12px; grid-template-columns: 1fr; 
    }
    @media (min-width: 860px){ .twocol{grid-template-columns: 1fr 1fr;} }

    .footer{margin-top:30px; color:var(--muted); font-size:.9rem}

    /* Print styles */
    @media print{
      :root{ --paper:#fff; --card:#fff; --ink:#000; }
      body{ background: #fff; }
      .toolbar, .nav{ display:none !important; }
      .wrap{ padding: 0 0 0; }
      header.hero{ background:#fff; border: none; box-shadow:none; }
      .card{ box-shadow:none; break-inside: avoid; }
      a{ color: #000; text-decoration: none; }
    }
  </style>
</head>
<body>
  <div class="wrap">
    <header class="hero" role="banner">
      <div class="kicker">
        <span class="pill" title="Evidence‑based">
          <!-- shield icon -->
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><path d="M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z"/></svg>
          NICE CKS (Oct 2024)
        </span>
        <span aria-hidden="true">•</span>
        <span>Type 1 Diabetes — Insulin Therapy</span>
      </div>
      <h1 class="title">Quick Reference Algorithm</h1>
      <p class="subtitle">Designed as a one‑page, at‑a‑glance aide‑mémoire for rapid decision‑making during consultations. Print‑ready, with dark mode.</p>
      <div class="toolbar" aria-label="Quick actions">
        <button class="btn ghost" id="modeBtn" type="button" title="Toggle dark mode">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"/></svg>
          Toggle dark mode
        </button>
        <button class="btn" type="button" onclick="window.print()" title="Print this page">
          <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9V2h12v7"/><path d="M6 18H4a2 2 0 0 1-2-2v-5a2 2 0 0 1 2-2h16a2 2 0 0 1 2 2v5a2 2 0 0 1-2 2h-2"/><path d="M6 14h12v8H6z"/></svg>
          Print
        </button>
      </div>
    </header>

    <!-- Quick Nav -->
    <nav class="nav" aria-label="Section navigation">
      <ul>
        <li><a href="#firstline">First‑line</a></li>
        <li><a href="#alternatives">If MDI not feasible</a></li>
        <li><a href="#pump">Pump & Closed‑Loop</a></li>
        <li><a href="#children">Children & Young People</a></li>
        <li><a href="#targets">SMBG Targets</a></li>
        <li><a href="#hypo">Hypoglycaemia</a></li>
        <li><a href="#technique">Technique & Sites</a></li>
        <li><a href="#accessories">Accessories</a></li>
        <li><a href="#interactions">Drug Interactions</a></li>
        <li><a href="#safety">Safety & Lifestyle</a></li>
      </ul>
    </nav>

    <main class="grid" role="main">
      <!-- First‑line -->
      <section id="firstline" class="card">
        <div class="eyebrow">Regimen</div>
        <h3>First‑line: Multiple Daily Injection (MDI) Basal–Bolus</h3>
        <div class="twocol">
          <div>
            <ul class="list-tight">
              <li><span class="badge good">Adults</span> Offer <strong>MDI basal–bolus</strong> to all. <em>Basal</em>: <strong>insulin detemir</strong> preferred (twice daily). If not acceptable/tolerated → <strong>insulin glargine</strong> once daily. <em>Bolus</em>: rapid‑acting analogue <strong>before meals</strong>.</li>
              <li>Do <strong>not</strong> recommend routine post‑meal rapid‑acting insulin.</li>
              <li>Do <strong>not</strong> start non‑basal–bolus regimens (mixed/basal‑only/bolus‑only) in newly diagnosed adults.</li>
            </ul>
          </div>
          <div>
            <div class="callout">
              <strong>Rationale.</strong> Basal–bolus best mirrors physiologic insulin; enables flexible dose matching to meals, activity and glucose pattern.
            </div>
          </div>
        </div>
        <p class="meta">Evidence summary: NICE CKS recommendations for adults; detemir first‑choice basal, rapid‑acting analogues for meals.</p>
      </section>

      <!-- Alternatives if MDI not feasible -->
      <section id="alternatives" class="card">
        <div class="eyebrow">Fallback Options</div>
        <h3>If MDI is not feasible</h3>
        <div class="twocol">
          <div>
            <ul class="list-tight">
              <li><span class="badge info">Adults</span> Consider <strong>twice‑daily mixed human insulin</strong> (biphasic). If hypoglycaemia affecting QoL → trial <strong>analogue mixed</strong>.</li>
              <li><span class="badge info">Children</span> If MDI unsuitable → consider <strong>insulin pump (CSII)</strong> via specialist team.</li>
            </ul>
          </div>
          <div>
            <div class="callout"><strong>Note.</strong> Choice should reflect patient preference, lifestyle and acquisition cost when alternatives are needed.</div>
          </div>
        </div>
      </section>

      <!-- Pump & Closed‑Loop -->
      <section id="pump" class="card">
        <div class="eyebrow">Technology</div>
        <h3>When to use Pump (CSII) & Hybrid Closed‑Loop</h3>
        <div class="twocol">
          <div>
            <h4 style="margin:.25rem 0">Pump therapy (CSII)</h4>
            <ul class="list-tight">
              <li>Consider if <strong>disabling hypoglycaemia</strong> on optimized MDI, <em>or</em> HbA1c <strong>≥ 69 mmol/mol (≥ 8.5%)</strong> despite high‑level support.</li>
              <li>Initiate and follow‑up within a trained <strong>specialist team</strong>; provide structured education.</li>
            </ul>
          </div>
          <div>
            <h4 style="margin:.25rem 0">Hybrid closed‑loop (Adults)</h4>
            <ul class="list-tight">
              <li>Offer if HbA1c <strong>≥ 58 mmol/mol (≥ 7.5%)</strong>, <em>or</em> <strong>disabling hypoglycaemia</strong> persists despite best use of CSII and/or CGM (rtCGM/isCGM).</li>
            </ul>
          </div>
        </div>
      </section>

      <!-- Children & Young People -->
      <section id="children" class="card">
        <div class="eyebrow">Paediatrics</div>
        <h3>Children & Young People (≥12 months)</h3>
        <div class="cols">
          <div>
            <ul class="list-tight">
              <li><strong>Start MDI at diagnosis.</strong></li>
              <li><strong>Adjust doses</strong> to SMBG patterns; use <strong>rapid‑acting analogue before meals</strong>.</li>
              <li>If MDI unsuitable → <strong>pump therapy</strong>; ensure specific training + ongoing specialist support.</li>
              <li>If suboptimal control → intensify team contact; consider regimen change.</li>
            </ul>
          </div>
        </div>
      </section>

      <!-- SMBG Targets -->
      <section id="targets" class="card">
        <div class="eyebrow">Monitoring</div>
        <h3>Self‑Monitoring Targets & Frequency</h3>
        <div class="twocol">
          <div>
            <h4 style="margin:.25rem 0">Adults</h4>
            <ul class="list-tight">
              <li>Test ≥ 4×/day (pre‑meals + bedtime); more often if driving, ill, exercising or targets unmet.</li>
              <li><strong>Waking:</strong> 5–7 mmol/L</li>
              <li><strong>Pre‑meal (day):</strong> 4–7 mmol/L</li>
              <li><strong>Post‑meal (≥ 90 min, if testing):</strong> 5–9 mmol/L</li>
              <li><strong>Bedtime:</strong> agree individually; align with waking target.</li>
              <li>CGM (rtCGM or isCGM) should be offered; still keep capillary checks for calibration/back‑up.</li>
            </ul>
          </div>
          <div>
            <h4 style="margin:.25rem 0">Children & Young People</h4>
            <ul class="list-tight">
              <li>Test ≥ 5×/day; more with activity or intercurrent illness.</li>
              <li><strong>Waking:</strong> 4–7 mmol/L</li>
              <li><strong>Pre‑meal:</strong> 4–7 mmol/L</li>
              <li><strong>Post‑meal:</strong> 5–9 mmol/L</li>
              <li><strong>Driving age:</strong> ≥ 5 mmol/L before driving.</li>
            </ul>
          </div>
        </div>
      </section>

      <!-- Hypoglycaemia -->
      <section id="hypo" class="card">
        <div class="eyebrow">Complications</div>
        <h3>Hypoglycaemia: Prevention & Treatment</h3>
        <div class="twocol">
          <div>
            <h4 style="margin:.25rem 0">Immediate treatment (able to swallow)</h4>
            <ul class="list-tight">
              <li>Give <strong>10–20 g fast‑acting carbohydrate</strong> (e.g., 3–6 glucose tablets; 90–180 mL sugary drink; 1–2 tubes glucose gel).</li>
              <li><strong>Children:</strong> ≈ 0.3 g/kg fast‑acting carb.</li>
              <li>Recheck in <strong>10–15 min</strong>; repeat if needed.</li>
              <li>When improved: if meal due → increase its carbs; if not → take <strong>long‑acting starchy snack</strong> (not required for pump users).</li>
            </ul>
            <h4 style="margin:.6rem 0 .25rem">Severe (unconscious/unable to swallow)</h4>
            <ul class="list-tight">
              <li><strong>IM glucagon immediately:</strong> < 8 years or < 25 kg → <strong>500 micrograms</strong>; otherwise <strong>1 mg</strong>.</li>
              <li>If no response within 10 min → urgent transfer for IV glucose.</li>
              <li>Once awake → give oral carbohydrate; monitor closely (risk of vomiting/recurrence).</li>
            </ul>
          </div>
          <div>
            <h4 style="margin:.25rem 0">If recurrent / nocturnal</h4>
            <ul class="list-tight">
              <li>Review regimen, injection technique, sites, lifestyle (meals/alcohol/activity), drug interactions and co‑morbidities.</li>
              <li>Consider nocturnal checks (2–3 am); bedtime snack; involve specialist team.</li>
            </ul>
            <h4 style="margin:.6rem 0 .25rem">Impaired awareness</h4>
            <ul class="list-tight">
              <li>Assess annually (Gold/Clarke). Reinforce education; prioritise strategies to <strong>avoid hypos</strong>.</li>
              <li>Consider <strong>CSII</strong> and/or <strong>CGM</strong> via specialist team if persisting or severe.</li>
            </ul>
          </div>
        </div>
      </section>

      <!-- Technique & Sites -->
      <section id="technique" class="card">
        <div class="eyebrow">Administration</div>
        <h3>Injection Technique, Sites & Storage</h3>
        <div class="cols">
          <div>
            <ul class="list-tight">
              <li>Use insulin at <strong>room temperature</strong>; check expiry; read the PIL.</li>
              <li>Cloudy insulin: <strong>invert/roll ≥ 10×</strong> (do not shake). Prime pen before each dose. New needle each time.</li>
              <li>Inject at <strong>90°</strong>; insert fully; leave needle in for <strong>5–10 s</strong> (longer for big doses). Split doses > 50 U.</li>
              <li>Rotate sites; do not inject into <strong>lipohypertrophy</strong> lumps; examine skin regularly.</li>
            </ul>
          </div>
          <div>
            <ul class="list-tight">
              <li><strong>Site speed:</strong> abdomen (fastest) → arm (med‑fast) → thigh (slower) → buttocks (slowest).</li>
              <li><strong>Storage:</strong> spares in fridge <strong>2–8 °C</strong> (do not freeze). In‑use: room temp (usually up to <strong>28 days</strong>); protect from heat/sunlight.</li>
            </ul>
          </div>
        </div>
      </section>

      <!-- Accessories -->
      <section id="accessories" class="card">
        <div class="eyebrow">Equipment</div>
        <h3>Essential Accessories</h3>
        <div class="cols">
          <div>
            <ul class="list-tight">
              <li>Injection devices: syringes, disposable or reusable pens, <strong>CSII</strong> (pump), or needle‑free (rare; severe needle phobia).</li>
              <li>Pen needles in <strong>varied lengths</strong> (4–12.7 mm); match to body fat; adjust if site problems.</li>
              <li>SMBG kit: meter (choice per team/patient), test strips, lancets.</li>
              <li>Ketone testing: blood/urine strips (blood ketone meters often not NHS‑prescribable).</li>
            </ul>
          </div>
          <div>
            <ul class="list-tight">
              <li><strong>Hypo rescue:</strong> glucose 40% oral gel; <strong>glucagon kit</strong> (1 mg; 500 mcg for small children).</li>
              <li>Sharps: needle‑clipping devices; 1 L or 5 L sharps bins.</li>
              <li><strong>Insulin Passport</strong> + patient information booklet; carry <strong>medical ID</strong> (e.g., MedicAlert).</li>
            </ul>
          </div>
        </div>
      </section>

      <!-- Interactions -->
      <section id="interactions" class="card">
        <div class="eyebrow">Medicines</div>
        <h3>Drug Interactions (selected)</h3>
        <div class="twocol">
          <div>
            <h4 style="margin:.25rem 0">Increase hypoglycaemia risk / lower insulin need</h4>
            <ul class="list-tight">
              <li><strong>Alcohol</strong> (also masks symptoms; advise snack before/after and regular testing).</li>
              <li>ACE inhibitors, beta‑blockers (mask tremor), fibrates, MAOIs, salicylates, sulphonamides, anabolic steroids, lanreotide/octreotide (may also ↑ requirements).</li>
            </ul>
          </div>
          <div>
            <h4 style="margin:.25rem 0">Reduce insulin effect / raise insulin need</h4>
            <ul class="list-tight">
              <li>Corticosteroids, danazol, diuretics (loop/thiazide), glucagon, growth hormone, levothyroxine, oral contraceptives, sympathomimetics (adrenaline/salbutamol/terbutaline).</li>
            </ul>
          </div>
        </div>
      </section>

      <!-- Safety & Lifestyle -->
      <section id="safety" class="card">
        <div class="eyebrow">Safety</div>
        <h3>Safety, Driving & Lifestyle</h3>
        <div class="cols">
          <div>
            <ul class="list-tight">
              <li>Use only <strong>prescribed/recommended devices</strong>. Do not withdraw insulin from pens with syringes.</li>
              <li><strong>Education:</strong> hypo awareness/management; sick‑day rules; technology use (CGM/pump).</li>
              <li><strong>Driving (DVLA):</strong> test just before travel and then every 2 h; carry fast‑acting carbs; if low, stop safely, treat, and wait <strong>≈ 45 min after normalisation</strong> before resuming.</li>
            </ul>
          </div>
          <div>
            <ul class="list-tight">
              <li><strong>Travel:</strong> carry meds & sharps in hand luggage; obtain clinician letter; check travel insurance covers T1D.</li>
              <li><strong>Car insurance:</strong> notify insurer if on insulin therapy.</li>
            </ul>
          </div>
        </div>
        <p class="meta">Always individualise goals and regimens to the person’s preferences, tolerance and life context.</p>
      </section>

      <p class="footer">Source: NICE Clinical Knowledge Summaries — Insulin therapy in type 1 diabetes (last revised Oct 2024). This page condenses guidance for rapid reference and does not replace specialist advice.</p>
    </main>
  </div>

  <script>
    const btn = document.getElementById('modeBtn');
    btn?.addEventListener('click', ()=>{
      const root = document.documentElement;
      const next = root.getAttribute('data-theme') === 'dark' ? 'light' : 'dark';
      root.setAttribute('data-theme', next);
      btn.blur();
    });
  </script>
</body>
</html>
